Centre for Pharmacoepidemiology - CPE
In October 2005, Karolinska Institutet established the Centre for Pharmacoepidemiology, with the explicit purpose to create a centre of academic excellence in pharmacoepidemiology, to meet the demands from stakeholders in society and industry for expertise and consultation in this field.
This centre will meet growing demands, both nationally and internationally, for data on drug safety, drug utilization and rational drug use, including pharmacogenetics. Sweden has through its national healthcare databases, biobanks together with high levels of epidemiological, pharmacological and other expertise a unique opportunity to meet these demands.
Health care providers, regulatory agencies and the pharmacological industry have identified drug safety, and rational drug use together with use of genetics and biomarkers as the most important issues for pharmacoepidemiological research. Collaboration has been established with national and international research groups.
CPE is located in the Unit for Clinical Epidemiology at the Department of Medicine, Karolinska University Hospital, Solna and linked with other groups within epidemiology and pharmacology at Karolinska Institutet. CPE is currently located at the Unit of Clinical Epidemiology at the Department of Medicine, Karolinska University Hospital, Solna and linked to other groups within epidemiology and pharmacology at Karolinska Institutet.
Services and methods
CPE will focus on drug safety evaluation using data from the Swedish national registers. We have identified four research areas where we in particular can provide expert competence:
- Drugs during pregnancy
- Drug utilization
- Chronic diseases and drugs
- New and expensive drugs
Please contact us for more information.